Sign in →

Test ID: UBT Helicobacter pylori Breath Test

Reporting Name

H. pylori C Urea Breath Test

Useful For

Diagnostic testing for Helicobacter pylori infection in patients suspected to have active H pylori infection


Monitoring response to therapy


This test is not appropriate for asymptomatic people.

Testing Algorithm

See Helicobacter pylori Diagnostic Algorithm in Special Instructions

Specimen Type


Advisory Information

An alternative test for the diagnosis of active Helicobacter pylori infection in patients is the HPFRP / Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces, which requires a different collection.

Necessary Information

A completed Pediatric UHR Calculation Information card (see Special Instructions) is required for patients between 3 and 17 years old. Testing may be delayed if this information is not received with the specimen.

Specimen Required

Patient Preparation:

1. Patient should be fasting for 1 hour.

2. Patients should not have taken bismuth/Tritec, antibiotics, proton-pump inhibitors (eg, Prilosec, Prevacid, Aciphex, Protonix, and Nexium) or Pepto-Bismol for 2 weeks prior to testing. If these instructions are not followed, test results may be inaccurate.

3. Histamine 2-receptor antagonists (H[2]RAs) such as Pepcid, Tagamet, Axid, or Zantac should be discontinued for 24 to 48 hours before the BreathTek UBT test is administered. If these instructions are not followed, test results may be inaccurate.

4. Carafate (sucralfate) does not interfere with the test. Use of antacids does not affect the accuracy of this assay.

Supplies: H. Pylori Breath Kit (T375: fees apply)

Collection Instructions:

1. Do not collect if patient is younger than 3 years of age.

2. Follow instructions included with kit.

Specimen Minimum Volume

Bag of ’’breath’’ must be full

Specimen Stability Information

Specimen Type Temperature Time Special Container
Breath Ambient 7 days BREATH TEST BAG

Reference Values


Reference values apply to all ages.

Day(s) and Time(s) Performed

Monday through Friday, Sunday; 6:30 a.m.-5 p.m.

Test Classification

This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
UBT H. pylori C Urea Breath Test 29891-9


Result ID Test Result Name Result LOINC Value
81590 H. pylori C Urea Breath Test 29891-9

Clinical Information

The causal relationship between the urease-producing bacterium, Helicobacter pylori, and chronic active gastritis, duodenal ulcer, and nonulcer dyspepsia is well established. Conventional methods for the diagnosis of active H pylori infection include evaluation of biopsied gastric tissue by histopathology and culture. Less invasive assays include testing for the presence of H pylori by polymerase chain reaction (PCR) in stool specimens and detection of H pylori urease production by the urea breath test (UBT). Serologic testing for the presence of IgM/IgG/IgA-class antibodies to H pylori is also performed; however, this is not recommended by either the American College of Gastroenterologists nor the American Gastroenterological Association (AGA) as an accurate marker for active disease. These serologic markers can remain elevated despite resolution of active disease and may lead to misdiagnosis and inappropriate treatment.


Recommendations for use of the (13)C-UBT (Meretek) were recently provided by the Digestive Health Initiative, a joint committee assembled with representatives from the AGA, the American Society for Gastrointestinal Endoscopy (ASGE), and the American Association for the Study of Liver Diseases (AASLD).(1) These recommendations include the following statements:

"When endoscopy is not clinically indicated, the primary diagnosis of H pylori infection can be made serologically or with the UBT. When endoscopy is clinically indicated, the primary diagnosis should be established by biopsy urease testing and/or histology. Available evidence suggests that confirmation of H pylori eradication is not mandatory in most situations because of costs associated with testing. However, for selected patients with complicated ulcer disease, low-grade gastric mucosa-associated lymphoid tissue lymphoma, and following resection of early gastric cancer, it is appropriate to confirm eradication. In other situations, the decision to confirm H pylori eradication should be made on a case-by-case basis."


This consensus group further specifies that there is no indication to test asymptomatic people and that testing for H pylori is only recommended if treatment is planned.


The (13)C-UBT) is a highly sensitive and specific noninvasive, nonradioactive test for diagnosing H pylori infection prior to antimicrobial treatment and for assessing whether the organism has been successfully eradicated following antimicrobial therapy.


In 2 recent large prospective studies, the (13)C-UBT was shown to be as, or more, sensitive and specific for diagnosing H pylori active infection than culture, stain, rapid urease testing of biopsy tissue, or serology.


When the test is used to assess eradication, it should be performed 4 to 6 weeks after completion of antimicrobial treatment.


See Helicobacter pylori Diagnostic Algorithm in Special Instructions.


The Helicobacter pylori urea breath test can detect very low levels of H pylori and, by assessing the entire gastric mucosa, avoids the risk of sampling errors inherent in biopsy-based methods. In the absence of gastric H pylori, the (13)C-urea does not produce (13)CO2 in the stomach.


A negative result does not rule out the possibility of H pylori infection. If clinical signs are suggestive of H pylori infection, retest with a new specimen or by using an alternative method.


A false-positive test may occur due to urease associated with other gastric spiral organisms observed in humans such as Helicobacter heilmannii.


A false-positive test could occur in patients who have achlorhydria.

Clinical Reference

1. Talley NJ, Vakil NB, Moayyedi P: American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129:1756-1780

2. Chey WD, Leontiadis GI, Howden CW, Moss SF: ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563

3. Talley NJ, Ford AC: Functional dyspepsia. N Engl J Med. 2015 Nov 5;373(19):1853-63. doi: 10.1056/NEJMra1501505

Analytic Time

Same day/1 day

Method Name

Infrared Spectrophotometry (SP)


1. For patients between 3 and 17 years old, the Pediatric UHR Calculation Information card is required, see Special Instructions.

2. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Microbiology Test Request (T244)

-Gastroenterology and Hepatology Client Test Request (T728)

Mayo Clinic Laboratories | Gastroenterology Catalog Additional Information:

mml-gi-id, mml-gi-intestinal-infections, mml-gi-intestinal-infections-hpylori